AmeriHealth Caritas™
New Hampshire

To: AmeriHealth Caritas New Hampshire Providers

Date: November 18, 2025

Subject: Expand access to cervical cancer screening with HPV self-collection

Summary: The FDA-approved HPV self-collection in clinics expands access to cervical cancer screening for those who may face barriers to traditional screening modalities.

The FDA recently cleared the use of human papillomavirus (HPV) patient self-collection modalities in the clinical setting. In addition to established methods like Pap testing, co-testing, and primary HPV testing, HPV self-collection offers a valuable testing option to support our members.

HPV self-collection testing aligns with current NCQA HEDIS CCS-E measure specifications. By incorporating self-collection into your practice, you can help lower care barriers and offer more personalized screening options.

HPV self-collection allows patients to collect their own vaginal sample in a clinical environment using a simple swab. This approach can be effective for reaching individuals who are under screened due to factors such as discomfort with pelvic exams, cultural or language barriers, lack of access to care, or past trauma. By offering self-collection, providers can expand screening access, promote early detection of cervical cancer, and support equitable care delivery across diverse populations.

How do I order HPV self-collection swabs and obtain additional information?
For clinicians that utilize **Quest**, you can order HPV self-collections for your patients by using *test code 14263, HPV DNA (16, 18, Other High Risk), PCR, Vaginal Self-Collected" (supply item K195).*

For health systems **with their own labs**, please speak to your laboratory director about options within your lab.

The HPV self-swab can meet the screening criteria for individuals ages 30-65 years of age who do not require cytology. The specimen is obtained through a vaginal self-collection.

The swab is recommended when the patient and the healthcare provider determine that it is not possible to obtain a cervical specimen.

How is the Test Billed?
The test is billed by the **CPT code 87626**. This meets the requirement for HEDIS for the Cervical Cancer Screening guidelines.

More Information
The Cervical Cancer Screening HEDIS® Measure Guidelines include the following:

The percentage of women 21-64 years of age who were screened for cervical cancer using any of the following criteria:

• Women ages 21-64 who had cervical cytology performed within the last 3 years.

• Women ages 30-64 who had cervical high-risk human papillomavirus (hrHPV) testing performed within the last 5 years.

• Women ages 30-64 who had cervical cytology/high-risk human papillomavirus (hrHPV) co-testing within the last 5 years.

The American Society for Colposcopy and Cervical Pathology offers their "Official Cervical Cancer Screening & Management Guidelines" to support decision-making. For more information, please see https://www.asccp.org/.

Questions?
If you have questions about this communication, please contact your Provider Network Management Account Executive or the Provider Services department at **1-888-599-1479**.
Thank you for your participation in our network and your continued commitment to the care of our members.